This content is from: Premium
This Could Be the Next Biopharma IPO
Several major hedge funds are poised to benefit if Acelyrin’s offering is successful.
Another fledgling biopharma company is looking to test the IPO market — and several well-known hedge funds hope to reap the benefits. Acelyrin, a late-stage clinical biopharma company focused on “transformative medicines,” recently filed plans to go public. The company has not yet disclosed
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.